Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
OPA1-03076 detects cJun N-terminal kinase 1 (JNK1) from human samples. This antibody does not detect JNK2 or JNK3.
OPA1-03076 has been successfully used in Western blot procedures. By Western blot, this antibody detects an ~46 kDa protein representing JNK1 from PC12 cell lysate.
The OPA1-03076 immunizing peptide derived is derived from an internal region within human JNK1.
MAPK8 (JNK1) is activated by the presence of misfolded proteins in the endoplasmic reticulum. It is also a crucial mediator of insulin resistance and obesity. It belongs to the MAPK superfamily of stress-activated protein kinases. MAPKs are Serine-threonine protein kinases that are activated in response to a variety of extracellular stimuli, and mediate signal transduction from the cell surface to the nucleus. JNK is involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. JNK pathways are activated by stress and inflammatory signals. JNK is expressed as ten different isoforms due to differential mRNA splicing. The predominant forms are JNK1 and JNK2.
仅用于科研。不用于诊断过程。未经明确授权不得转售。